Barclays keeps Boston Scientific at Equal-Weight and cuts target to $45
Barclays kept its Equal-Weight rating on Boston Scientific and lowered its price target from $48 to $45, a 6.2% cut. Reported by TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Barclays left its Equal-Weight rating on Boston Scientific unchanged but reduced its price target from $48 to $45, a 6.2% decrease. According to TradingView, the stock closed at $42.69 on October 29, and the new target implies roughly 5.4% upside from that level.
Across the five most recent analyst notes on the stock over the past 30 days, targets ranged from $44 to $52. On the same day, Jefferies downgraded the shares to Hold with a $46 target, while Citigroup kept its Neutral rating with a $44 target.
why it matters
Rating and price-target updates like this are published regularly and rarely move the broader market. For medtech investors, the overall pattern of valuations across the sector matters more than a single bank's target change.
tags
instruments
sources
- Barclays maintains Boston Scientific at Equal-Weight, lowers price target to $45 from $48 — TradingView, 30 October 2026 at 13:56 UTC
- Barclays maintains DoorDash at Equal-Weight, lowers price target to $205 from $230 — TradingView, 30 October 2026 at 14:20 UTC
- Barclays maintains D.R. Horton at Equal-Weight, lowers price target to $125 from $130 — TradingView, 30 October 2026 at 14:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗